Skip to content
Screener

Eli Lilly LLY Reportable Segment — Interest Expense

Similar metrics at other companies

Snowflake logo
SNOWReportable Segment — Interest Expense
-$2.08M-0.4%
Marvell Technology, Inc. logo
MRVLReportable Segment — Interest Expense
$52.8M+8.4%
OLP
OLPXReportable Segment — Interest Expense
$7.13M-48.0%
nCino, Inc. logo
NCNOReportable Segment — Interest Expense
$4.48M+0.7%
NSA
NSAReportable Segment — Interest Expense
$39.26M-3.0%
Lemonade logo
LMNDReportable Segment — Interest Expense
$6.2M+87.9%

Other financials

Income statement

See full
Revenue$23.0B+47.7%
Gross profit$19.7B+50.3%
Net income$7.1B+25.3%
EPS (diluted)$7.94+26.2%

Balance sheet

See full
Cash & equivalents$9.0B+165%
Total debt$54.9B+37.6%
Total equity$33.9B+85.4%
Total assets$142.28B+41.0%

Cash flow

See full
Operating cash flow$10.7B+246%
CapEx$2.9B+72.8%
Free cash flow$7.8B+458%

Valuation

See full
Market cap$1.06T+58.6%
Enterprise value$1.11T+56.9%
P/E39.8×-8.8×
P/S13.3×+0.8×

Profitability

See full
Gross margin83.4%+0.8pp
Net margin33.5%+7.6pp
FCF margin22.8%+13.7pp

Returns & leverage

See full
Return on equity102.4%+15.7pp
Debt / equity1.6×-0.6×
Current ratio1.4×+0.1×

Where this comes from

Reported directly by Eli Lilly in its filing.

Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.

The source filing: Eli Lilly’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 2:40 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000059478-26-000081
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Early-stage research and development(1)1,4501,1562,7152,146
Late-stage research and development(1)2,3682,1804,6133,924
Marketing, selling, and administrative3,4302,7536,3645,221
Acquired in-process research and development2,7761543,3601,726
Other segment items(2)2,5871,2074,3842,177
Net income$7,095$5,661$14,491$8,420
Interest expense$345$249$677$493
Expenditures for long-lived assets(3)2,9061,9855,3443,502

Item 1. Financial Statements

FAQ

What is Eli Lilly's reportable segment — interest expense?
Eli Lilly (LLY) reported reportable segment — interest expense of $345M in Q2 2026.
How has Eli Lilly's reportable segment — interest expense changed year-over-year?
Eli Lilly's reportable segment — interest expense increased by 38.6% year-over-year, from $249M to $345M.
What is the long-term trend for Eli Lilly's reportable segment — interest expense?
Over 2 years (2022 to 2024), Eli Lilly's reportable segment — interest expense has grown at a 53.4% compound annual growth rate (CAGR), from $331.6M to $780.6M.
What does reportable segment — interest expense mean?
Represents the cost incurred by the reportable segment for borrowed funds used to finance operations or capital projects. This metric reflects the segment's share of debt-related financing costs and is essential for assessing the segment's standalone capital structure efficiency.

Ask your AI about Eli Lilly's reportable segment — interest expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude